- Too hot by day, Dubai's floodlit beaches are packed at night
- Is music finally reckoning with #MeToo?
- Fans hail Trump's 'guts' as he returns to site of rally shooting
- Lebanon state media says 'very violent' Israeli strikes hit south Beirut
- Guardians maul Tigers, miracle Mets rally in MLB series openers
- Lebanon state media says Israeli strikes hit south Beirut
- Miami on track for MLS record points after win in Toronto
- Madrid beat Villarreal but Carvajal suffers knee injury
- Madrid beat Villarreal to move level with Liga leaders Barcelona
- Monaco take top spot in Ligue 1 with win at Rennes
- French rugby player on rape charge whistled but 'serene' on return
- Madrid beat Villarreal to level Liga leaders Barca
- Thuram treble fires Inter past Torino and up to second
- 'Fight': defiant Trump jets in to site of rally shooting
- Toddler among 3 dead in migrant Channel crossings
- Mexico City's new mayor sworn in with pledges on water, housing
- Israel on alert ahead of Hamas attack anniversary
- Guardians maul Tigers in MLB playoff series opener
- Macron criticises Israel on Gaza, Lebanon operations
- French rugby player whistled but 'serene' on return amid ongoing rape case
- Kovacic stars as Man City sink Fulham to get title bid back on track
- Retegui hat-trick fires five-star Atalanta to hammering of Genoa
- Heavyweights Australia, England off to World Cup winning starts
- Visiting UN refugee agency chief decries 'terrible crisis' in Lebanon
- Spinners come to party as England defeat Bangladesh at T20 World Cup
- Search continues for missing in deadly Bosnia floods
- Man City sink Fulham to get title bid back on track
- France's Auradou whistled on Pau return in Perpignan loss amid ongoing rape case
- A 'forgotten' valley in storm-hit North Carolina, desperate for help
- Arsenal hit back in style after Southampton scare
- Thousands march for Palestinians ahead of Oct 7 anniversary
- Hezbollah heir apparent Safieddine out of contact after strikes
- Liverpool stay top of Premier League as Arsenal, Man City win
- In dank Tour of Emilia, Pogacar shines in rainbow jersey
- DR Congo launches mpox vaccination drive, hoping to curb outbreak
- Trump returns to site of failed assassination
- Careless Leverkusen held to Bundesliga draw
- O'Brien's 'superstar' Kyprios posts landmark win on Arc weekend
- Toddler crushed to death in migrant Channel crossing
- Liverpool suffer Alisson injury blow
- Habosi helps Racing beat Vannes before Auradou's playing return
- Thousands march in London in support of Palestinians, 1 year after Oct 7
- Israel readying response to Iran missile attack
- Schutt, Mooney help Australia beat Sri Lanka in Women's T20 World Cup
- Liverpool extend Premier League lead with win at Palace
- Djokovic 'shakes rust off' to make third round of Shanghai Masters
- 'Imperfect' PSG fighting on all fronts - Luis Enrique
- Struggling Pakistan look to thwart adaptable England
- Child 'trampled to death' in asylum seekers' Channel crossing: minister
- Gauff fights back to set up Beijing final against Muchova
Strong trial results for Pfizer lung cancer drug
A Pfizer medicine has been shown to greatly reduce cancer progression and improve survival outcomes for people in the advanced stages of a form of lung cancer, results published Friday showed.
Lorlatinib, which is already approved and available under the brand name Lobrena in the United States, was tested in a clinical trial of hundreds of people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Roughly half received lorlatinib while the rest received crizotinib, an earlier generation drug.
After five years of follow-up time, more than half of patients treated with lorlatinib did not see their cancer progress.
"We're talking about patients with advanced metastatic disease -- so this is actually a truly unprecedented finding," Pfizer's Despina Thomaidou told AFP.
Sixty percent of patients receiving lorlatinib, an oral one a day tablet, were alive without disease progression after five years compared to 8 percent on crizotinib.
"There is an 81 percent reduction in the risk of progression or death," added Thomaidou.
Lung cancer is the leading cause of cancer deaths globally.
NSCLC accounts for more than 80 percent of lung cancers, with ALK-positive tumors responsible for roughly five percent of NSCLC cases, with roughly 72,000 new cases each year worldwide.
ALK-positive NSCLC mostly affects younger patients and is largely decoupled from lifestyle indicators such as smoking. It is also very aggressive -- 25-40 percent of people with ALK-positive NSCLC develop brain metastases within the first two years.
Lorlatinib penetrates the blood-brain barrier better than prior generation medicines, said Thomaidou, and works to inhibit tumor mutations that drive resistance.
Side effects of lorlatinib included swellings, weight gain and mental health problems.
The results were published at the annual meeting of the American Society of Clinical Oncology and in the Journal of Clinical Oncology.
A.Malone--AMWN